← ANALYST RATINGS · TIPRANKS
IDEAYA Biosciences (IDYA): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $54.88, the highest $65.00, the lowest $48.00. The average is +67.0% from the last price of $32.85.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $48.00 | Buy | +46.1% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $41.00 → $35.00−14.6% | Hold | +6.5% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| Unknown Analyst | William Blair | $51.00 | Buy | +55.3% | Initiated | 15.10.26on TipRanks Oct 16 00:05 | −0.3%next day −1.8% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $48.00 | Buy | +46.1% | Initiated | 13.10.26on TipRanks 16:35 | −0.1%next day −0.3% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $58.00 | Buy | +76.6% | Reiterated | 27.09.26on TipRanks 19:25 | +4.9%next day −0.8% · 5 days −1.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $44.00 | Buy | +33.9% | Reiterated | 23.09.26on TipRanks 01:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $41.00 | Hold | +24.8% | Reiterated | 23.09.26on TipRanks 01:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $42.00 | Hold | +27.9% | Reiterated | 23.09.26on TipRanks 01:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $41.00 | Hold | +24.8% | Reiterated | 23.09.26on TipRanks 01:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $43.00 → $42.00−2.3% | Hold | +27.9% | Downgrade | 23.09.26on TipRanks 01:06 | — | |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $65.00 | Buy | +97.9% | Reiterated | 10.09.26on TipRanks Sep 11 06:10 | −1.7%next day −0.5% · 5 days +2.5% | ↗ |
| Paul Jeng★★★★★★★★★★#9457 · hits 52% · avg −1.9% | Guggenheim | $54.00 → $57.00+5.6% | Buy | +73.5% | Reiterated | 09.09.26on TipRanks 07:30 | −0.8%next day −1.7% · 5 days −0.5% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $50.00 | Buy | +52.2% | Reiterated | 01.09.26on TipRanks 08:50 | +0.3%next day +0.1% · 5 days −4.1% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 01.09.26on TipRanks 08:05 | +0.3%next day +0.1% · 5 days −4.1% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $60.00 | Buy | +82.6% | Reiterated | 20.08.26on TipRanks 09:55 | +1.5%next day +1.0% · 5 days +5.7% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $38.00 → $41.00+7.9% | Hold | +24.8% | Reiterated | 20.08.26on TipRanks 02:07 | — | |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $66.00 → $62.00−6.1% | Buy | +88.7% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | −0.7%next day +0.6% · 5 days −0.5% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $45.00 → $42.00−6.7% | Buy | +27.9% | Reiterated | 06.08.26on TipRanks 15:35 | +0.7%next day +1.5% · 5 days 0.0% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $48.00 | Buy | +46.1% | Reiterated | 05.08.26on TipRanks 07:45 | 0.0%next day +0.7% · 5 days +2.2% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $48.00 | Buy | +46.1% | Reiterated | 04.08.26on TipRanks Aug 5 21:45 | +0.2%next day 0.0% · 5 days +2.1% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $50.00 | Buy | +52.2% | Reiterated | 09.06.26on TipRanks 06:10 | −10.5%next day −0.1% · 5 days +7.1% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $35.00 → $36.00+2.9% | Hold | +9.6% | Reiterated | 03.06.26on TipRanks Jun 4 08:35 | +2.6%next day +2.5% · 5 days +1.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 05.05.26on TipRanks 13:35 | −1.1%next day −1.6% · 5 days −4.4% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $31.00 → $52.00+67.7% | Buy | +58.3% | Reiterated | 05.04.26on TipRanks Apr 6 07:50 | −1.7%next day −4.5% · 5 days −2.6% | ↗ |
| Justin Zelin★★★★★★★★★★#4442 · hits 36% · avg +3.1% | BTIG | $62.00 | Buy | +88.7% | Reiterated | 04.11.25on TipRanks Nov 5 06:45 | −1.6%next day −3.0% · 5 days +3.9% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $40.00 | Buy | +21.8% | Reiterated | 04.11.25on TipRanks Nov 5 03:50 | −1.6%next day −3.0% · 5 days +3.9% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $30.00 → $33.00+10.0% | Hold | +0.5% | Reiterated | 21.10.25on TipRanks 04:50 | −4.3%next day −1.4% · 5 days +11.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering IDEAYA Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.44 at a price of $38.42 (+41.7%); now: $53.55 at $32.85 (+63.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 24 | 22 | 14 | 15 | 13 | 11 |
| Buy | 10 | 4 | 4 | 9 | 10 | 10 |
| Hold | 1 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.18 (from $-1.42 to $-0.84). Last quarter: $-1.22.
Sales
Next quarter’s sales estimate — $7M (from $0M to $35M). Last quarter: $9M.
Best top-analyst consensus in the sector · Healthcare
About IDEAYA Biosciences
- CEO: Yujiro S. Hata
- Employees: 145
- 7000 Shoreline Court, South San Francisco, CA, 94080, US
- www.ideayabio.com
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 47 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗